ArriVent Is Second Positive IPO Of 2024 After CG Oncology’s Debut

Cancer Drug Developer Closes Up 11.1%

 
• By Mandy Jackson
  
Skyscrapers Cityscape Downtown View, Boston Skyline Buildings. NIght time. IPO hologram.
The positive performance of the year's first two IPOs may drive future offerings • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business